tirzepatide sublingual Oral Pill: FDA-Approved Options Tirzepatide Oral Rapid Dissolve Sublingual

Tirzepatide is a once-weekly, dual-incretin peptide it activates both the GIP and the GLP-1 receptor from a single molecule and in published obesity trials it has produced some of the largest average weight reductions of any incretin agent studied to date

R1227-R1231.

The ATLAS Community Health Initiative is supported by UCLA Health, the David Geffen School of Medicine and a grant from the UCLA Clinical and Translational Science Institute (UL1TR001881)

Convenience: Our mobile IV therapy services come to you at your home or office, saving you time and effort

Other ingredients De-ionized water, vegetable glycerin, malic acid, citric acid, natural flavors, potassium sorbate (as preservative) and organic stevia leaf extract (enzyme-modified steviol glycosides)